Michael Heathman

835 total citations
24 papers, 604 citations indexed

About

Michael Heathman is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Michael Heathman has authored 24 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 6 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Oncology. Recurrent topics in Michael Heathman's work include Pharmacogenetics and Drug Metabolism (4 papers), Diabetes Management and Research (4 papers) and Diabetes Treatment and Management (4 papers). Michael Heathman is often cited by papers focused on Pharmacogenetics and Drug Metabolism (4 papers), Diabetes Management and Research (4 papers) and Diabetes Treatment and Management (4 papers). Michael Heathman collaborates with scholars based in United States, United Kingdom and Czechia. Michael Heathman's co-authors include Jenny Y. Chien, Vikram Sinha, Stuart Friedrich, Dinesh P. de Alwis, Mary Pat Knadler, Lisa M. O’Brien, Harald Dobnig, Julie Satterwhite, Paul D. Miller and Fernando Marín and has published in prestigious journals such as Journal of Clinical Oncology, Pharmaceutical Research and TrAC Trends in Analytical Chemistry.

In The Last Decade

Michael Heathman

23 papers receiving 579 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Heathman United States 12 170 135 127 113 85 24 604
Abhijit Barve United States 14 108 0.6× 221 1.6× 67 0.5× 34 0.3× 80 0.9× 37 663
Jace Nielsen United States 10 103 0.6× 104 0.8× 138 1.1× 32 0.3× 65 0.8× 19 397
Pascal Espié Switzerland 12 106 0.6× 92 0.7× 68 0.5× 37 0.3× 75 0.9× 21 625
Atalanta Ghosh United States 13 205 1.2× 149 1.1× 420 3.3× 49 0.4× 267 3.1× 20 791
Christian Leporini Italy 14 186 1.1× 116 0.9× 78 0.6× 54 0.5× 64 0.8× 24 715
Elliot Offman United States 14 132 0.8× 70 0.5× 43 0.3× 30 0.3× 71 0.8× 33 505
James W.K. Robertson United Kingdom 7 147 0.9× 60 0.4× 335 2.6× 67 0.6× 88 1.0× 7 847
Kim Stuyckens United States 15 340 2.0× 214 1.6× 35 0.3× 31 0.3× 196 2.3× 26 929
Dennis Swearingen United States 13 119 0.7× 81 0.6× 59 0.5× 32 0.3× 39 0.5× 28 444
Kyoko Matsuguma Japan 12 115 0.7× 76 0.6× 36 0.3× 64 0.6× 113 1.3× 16 636

Countries citing papers authored by Michael Heathman

Since Specialization
Citations

This map shows the geographic impact of Michael Heathman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Heathman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Heathman more than expected).

Fields of papers citing papers by Michael Heathman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Heathman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Heathman. The network helps show where Michael Heathman may publish in the future.

Co-authorship network of co-authors of Michael Heathman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Heathman. A scholar is included among the top collaborators of Michael Heathman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Heathman. Michael Heathman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Collins, Kimberly S., Blessed Winston Aruldhas, Ingrid F. Metzger, et al.. (2025). A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe. CPT Pharmacometrics & Systems Pharmacology. 14(12). 2095–2106.
2.
Haas, David M., et al.. (2022). Pharmacokinetics of vaginal versus buccal misoprostol for labor induction at term. Clinical and Translational Science. 15(8). 1937–1945. 4 indexed citations
3.
Heathman, Michael, et al.. (2022). P206 Model-predicted lymphocyte response and recovery profiles for the sphingosine 1-phosphate receptor modulators ozanimod and etrasimod. Poster presentations. A140.3–A141. 1 indexed citations
4.
Leohr, Jennifer, Michael Heathman, & Maria C. Kjellsson. (2020). Postprandial triglyceride reduction following acute treatment of a selective 5‐hydroxytryptamine‐2c agonist and characterization using a semi‐physiological model. Diabetes Obesity and Metabolism. 23(4). 1001–1010. 1 indexed citations
5.
Shen, Lei, et al.. (2019). Incorporating Placebo Response in Quantitative Systems Pharmacology Models. CPT Pharmacometrics & Systems Pharmacology. 8(6). 344–346. 3 indexed citations
6.
Tabernero, Josep, Atsushi Ohtsu, Kei Muro, et al.. (2017). Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 16(10). 2215–2222. 34 indexed citations
7.
Mo, Gary, John R. Baldwin, Debra Luffer‐Atlas, et al.. (2017). Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer. Clinical Pharmacokinetics. 57(3). 355–365. 21 indexed citations
8.
Heathman, Michael, Xuewei Cui, Jennifer A. Martin, et al.. (2015). Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clinical Pharmacokinetics. 55(5). 625–634. 75 indexed citations
9.
Tabernero, Josep, Atsushi Ohtsu, Kei Muro, et al.. (2015). Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.. Journal of Clinical Oncology. 33(3_suppl). 121–121. 19 indexed citations
10.
Skrivanek, Zachary, Brenda Gaydos, Jenny Y. Chien, et al.. (2014). Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD‐5). Diabetes Obesity and Metabolism. 16(8). 748–756. 49 indexed citations
11.
Schneck, Karen, et al.. (2012). Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator. Journal of Pharmacokinetics and Pharmacodynamics. 40(1). 53–65. 11 indexed citations
12.
Satterwhite, Julie, Michael Heathman, Paul D. Miller, et al.. (2010). Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis. Calcified Tissue International. 87(6). 485–492. 79 indexed citations
13.
Lobo, Evelyn D., Michael Heathman, Shobha Reddy, et al.. (2010). Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine. Clinical Pharmacokinetics. 49(5). 311–321. 28 indexed citations
14.
Ernest, C. Steven, Michael Heathman, & Rebecca E. Wrishko. (2009). Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis. The Journal of Clinical Pharmacology. 49(8). 973–983. 1 indexed citations
15.
Lobo, Evelyn D., Tonya Quinlan, Lisa O’Brien, Mary Pat Knadler, & Michael Heathman. (2009). Population Pharmacokinetics of Orally Administered Duloxetine in Patients. Clinical Pharmacokinetics. 48(3). 189–197. 37 indexed citations
16.
Chien, Jenny Y., Stuart Friedrich, Michael Heathman, Dinesh P. de Alwis, & Vikram Sinha. (2005). Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation. The AAPS Journal. 7(3). E544–E559. 119 indexed citations
17.
Skinner, Michael, Andrej Skerjanec, Mary Seger, et al.. (2003). Effect of age on the pharmacokinetics of duloxetine in women. British Journal of Clinical Pharmacology. 57(1). 54–61. 54 indexed citations
18.
Girard, P., Laurent Claret, S. Thomas Forgue, et al.. (2003). Qualification of An Osteoporosis Biomarker Model For Simulation. Clinical Pharmacology & Therapeutics. 73(2). 1 indexed citations
19.
Ring, Barbara J., Sandra R. B. Allerheiligen, Michael Heathman, et al.. (2000). A Population Approach to Enzyme Characterization and Identification: Application to Phenacetin O-Deethylation. Pharmaceutical Research. 17(12). 1531–1536. 10 indexed citations
20.
Heathman, Michael, et al.. (1989). Analytical applications of Raman spectroscopy in the pharmaceutical field. TrAC Trends in Analytical Chemistry. 8(1). 19–24. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abhijit Barve Breakdown of academic impact, for papers by Jace Nielsen Breakdown of academic impact, for papers by Pascal Espié Breakdown of academic impact, for papers by Atalanta Ghosh Breakdown of academic impact, for papers by Christian Leporini Breakdown of academic impact, for papers by Elliot Offman Breakdown of academic impact, for papers by James W.K. Robertson Breakdown of academic impact, for papers by Kim Stuyckens Breakdown of academic impact, for papers by Dennis Swearingen Breakdown of academic impact, for papers by Kyoko Matsuguma
Rankless by CCL
2026